• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHANG Yuan, CHENG Yulan, ZHOU Jinpei, ZHANG Huibin. Advances on receptor tyrosine kinase inhibitors taking c-Met as anti-tumor target[J]. Journal of China Pharmaceutical University, 2015, 46(1): 16-27. DOI: 10.11665/j.issn.1000-5048.20150102
Citation: ZHANG Yuan, CHENG Yulan, ZHOU Jinpei, ZHANG Huibin. Advances on receptor tyrosine kinase inhibitors taking c-Met as anti-tumor target[J]. Journal of China Pharmaceutical University, 2015, 46(1): 16-27. DOI: 10.11665/j.issn.1000-5048.20150102
shu

Advances on receptor tyrosine kinase inhibitors taking c-Met as anti-tumor target

More Information
    Graphical Abstract
    • Abstract
  • c-Met receptor tyrosine kinase plays an important role in signaling pathways including cell proliferation, metabolism as well as tumorigenic growth, migration and angiogenesis. c-Met has emerged as an attractive target for cancer therapy. Moreover, the interactive cross-talk between c-Met signaling and several other signaling pathways underlies a key effect for resistance of anti-cancer drugs. Thus, multi-target inhibitors become a new approach to cancer therapy. This paper introduces the c-Met signaling pathway and the resistance of kinase inhibitors caused by the cross-talk between c-Met and other membrane receptors and then will reviews the progress of single-target and multi-target c-Met inhibitors.
    • FullText(HTML)
    • References (52)
  • [1]
    Maroun CR,Rowlands T.The Met receptor tyrosine kinase:a key player in oncogenesis and drug resistance[J].Pharmacol Ther,2014,142(3):316-338.
    [2]
    Cui JJ.Targeting receptor tyrosine kinase MET in cancer:small molecule inhibitors and clinical progress[J].J Med Chem,2014,57(11):4427-4453.
    [3]
    Giordano S,Columbano A.Met as a therapeutic target in HCC:facts and hopes[J].Hepatol,2014,60(2):442-452.
    [4]
    Masami H,Masahiro S,Takashi,et al.Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension[J].Endocrinology,2005,146(11):4682-4689.
    [5]
    Vaupel P.The role of hypoxia-induced factors in tumor progression[J].Oncologist,2004, 9(5):10-17.
    [6]
    Jeffrey A,Kreshnik Z,Tetsuya M,et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J].Science,2007,316(5827):1039-1043.
    [7]
    Alexa BT,Kreshnik Z,Wu YL,et al.Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC[J].Cancer Cell,2010,17(1):77-88.
    [8]
    Ted LU,Torsten H,Sheila JM.Discovery of small molecule c-Met inhibitors:evolution and profiles of clinical candidates[J].Anti-Cancer Agents Med Chem,2010,10:7-27.
    [9]
    Koenig M,Cui JR,Chen WC,et al.Indolinone hydrazides as c-met inhibitors:US,WO 2005005378 A2[P].2003-02-07[2014-10-29] .
    [10]
    Vojkovsky T,Koenig M.Tetracyclic compounds as c-met inhibitors:US,WO 2005004808A2[P].2005-01-20[2014-10-29] .
    [11]
    Cui JJ,Michele M,Mitchell N,et al.Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor(c-MET)protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3] triazolo[4,5-b] pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol(PF-04217903)for the treatment of cancer[J].J Med Chem,2012,55(18):8091-8109.
    [12]
    Cui JJ,Hong S,Michelle TD,et al.Lessons from(S)-6-(1-(6-(1-methyl-1H-pyrazol -4-yl)-[1,2,4] triazolo[4,3-b] pyridazin-3-yl)ethyl )quinoline(PF-04254644),an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats[J].J Med Chem,2013,56(17):6651-6665.
    [13]
    Peters S,Adjei AA.MET:a promising anticancer therapeutic target[J].Nat Rev Clin Oncol,2012,9(6):314-326.
    [14]
    Sharon D,Jason B,Thomas P,et al.Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications[J].Drug Metab Dispos,2010,38(8):1277-1285.
    [15]
    Byung HP,Kyung HJ,Yun SM,et al.KRC-327,a selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity[J].Cancer Lett,2013,331(2):158-166.
    [16]
    Albrecht BK,Harmange JC,Bauer D,et al.Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase[J].J Med Chem,2008,51(10),2879-2882.
    [17]
    Christiane MB,Alessandro AB,Brian KA,et al.Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors[J].Bioorg Med Chem Lett,2012,22(12):4089-4093.
    [18]
    Neru M, Jeay S, Li YZ, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity[J].Mol Cancer Ther,2010,9(6):1544-1553.
    [19]
    Gretchen MS,Chen XT,David KW,et al.Identification of pyrrolo[2,1-f][1,2,4] triazine-based inhibitors of Met kinase[J].Bioorg Med Chem Lett,2008,18(6):1945-1951.
    [20]
    Cai ZW,Wei DN,Gretchen M,et al.Discovery of orally active pyrrolopyridine-and aminopyridine-based Met kinase inhibitors[J].Bioorg Med Chem Lett,2008,18(11):3224-3229.
    [21]
    Lu W,Ai J,Shen YY,et al.SOMCL-863,a novel,selective and orally bioavailable small-molecule c-Met inhibitor,exhibits antitumor activity both in vitro and in vivo[J].Cancer Lett,2014,351(1):143-150.
    [22]
    Craig AZ,Jay PT,Lisa DA,et al.2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines[J].Bioorg Med Chem Lett,2011,21(2):660-663.
    [23]
    Alessandro F,Francesco C,Andrea K,et al.Identification of new aminoacid amides containing the imidazo[2,1-b] benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling[J].Eur J Med Chem,2012,47(1):239-254.
    [24]
    Hong SW,Jung KH,Byung HP,et al.KRC-408,a novel c-Met inhibitor,suppresses cell proliferation and angiogenesis of gastric cancer[J].Cancer Lett,2013,332(1):74-82.
    [25]
    He CX, Ai J, Xing WQ, et al. Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells[J].Acta Pharmacol Sin,2014,35(1):89-97.
    [26]
    Kang ST,Kim EY,Raghavendra A,et al.Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors[J].Bioorg Med Chem Lett,2014,24:5093-5097.
    [27]
    Joanne VA,Catherine B,Kevin B,et al.The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach[J].Bioorg Med Chem Lett,2011,21(18):5224-5229.
    [28]
    Xu JM,Ai J,Liu S,et al.Design and synthesis of 3,3′-biscoumarin-based c-Met inhibitors[J].Org Biomol Chem,2014,12(22):3721-3734.
    [29]
    Liu XD,Wang Q,Yang GJ,et al.A novel kinase inhibitor,INCB28060,blocks c-MET-dependent signaling,neoplastic activities,and cross-talk with EGFR and HER-3[J].Clin Cancer Res,2011,17(22):7127-7138.
    [30]
    Friedhelm B,Bettina F,Manja FH,et al.EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors[J].Clin Cancer Res,2013,19(11):2941-2951.
    [31]
    Mohammadi M,Froum S,Hamby JM,et al.Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain[J].MBO J,1998,17(20):5896-5904.
    [32]
    Alex K,Casie R,Kim LR,et al.Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia[J].Nat Med,2012,18(7):1118-1122.
    [33]
    Marta PR,Elizabeth A,James H,et al.Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J].Cancer Cell,2009, 15(3):220-231.
    [34]
    Barbara S, Toshina IO, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors[J].Cancer Discov,2012,2(3):270-287.
    [35]
    Hal EC,Anindya D,Carlos SA,et al.PHA665752,a small-molecule inhibitor of c-Met,inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met positive neuroblastoma cells[J].Bio Med Central Cancer,2009,9:411-413.
    [36]
    James GC,Helen YZ,Maria EA,et al.Cytoreductive antitumor activity of PF-2341066,a novel inhibitor of anaplastic lymphoma kinase and c-Met,in experimental models of anaplastic large-cell lymphoma[J].Mol Cancer Ther,2007,6(12):3314-3322.
    [37]
    Steinig AG.Novel 6-aminofuro[3,2-c]pyridines as potent,orally efficacious inhibitors of cMET and RON kinases[J].Bioorg Med Chem Lett,2013, 23(15):4381-4387.
    [38]
    Fujiwara.Quinoline derivative and quinazoline derivative inhibiting self-phosphoraylation of hepatocytus proliferator receptor and medicinal composition containning the same:US,8324245B2[P].2012-12-04[2014-10-29] .
    [39]
    Stephen C,Franck R,Granger MC,et al.Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases[J].Bioorg Med Chem Lett,2008,18(9):2793-2798.
    [40]
    Yakes FM, Jason C, Jenny T, et al. Cabozantinib(XL184), a novel MET and VEGFR2 inhibitor,simultaneously suppresses metastasis,angiogenesis,and tumor growth[J].Mol Cancer Ther,2011,10(12):2298-2308.
    [41]
    Qian F,Stefan E,Kyoko Y,et al.Inhibition of tumor cell growth,invasion,and metastasis by EXEL-2880(XL880,GSK1363089),a novel inhibitor of HGF and VEGF receptor tyrosine kinases[J].Cancer Res,2009,69(20):8009-8016.
    [42]
    Takayuki N,Osamu T,Atsumi Y,et al.E7050:a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models[J].Cancer Sci,2010,101(1):210-215.
    [43]
    Li S,Zhao YF,Wang KW,et al.Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors[J].Bioorg Med Chem,2013,21(11):2843-2855.
    [44]
    Qi BH,Mi B,Zhai X,et al.Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors[J].Bioorg Med Chem,2013,21(17):5246-5260.
    [45]
    Gretchen MS,An YM,Cai ZW,et al.Discovery of N-(4-(2-amino-3-chloropyridin -4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide(BMS-777607),a selective and orally efficacious inhibitor of the Met kinase superfamily[J].J Med Chem,2009,52:1251-1254.
    [46]
    Yoshiko A,Kazuhide N,Akio M,et al.A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities[J].Mol Cancer Ther,2013,12(6):913-924.
    [47]
    Yan SB,Victoria LP,Rose A,et al.LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET,MST1R,and other oncoproteins,and displays anti-tumor activities in mouse xenograft models[J].Invest New Drugs,2013,31(4):833-844.
    [48]
    Liu LB,Mark HN,Lee M,et al.Structure-based design of novel class II c-Met inhibitors:2.SAR and kinase selectivity profiles of the pyrazolone series[J].J Med Chem,2012,55(5):1868-1897.
    [49]
    She NF,Zhuo LS,Jiang W,et al.Design,synthesis and evaluation of highly selective pyridone-based class II MET inhibitors[J].Bioorg Med Chem Lett,2014,24(15):3351-3355.
    [50]
    Liu ZQ, Ai J, Peng X, et al. Novel 2, 4-diarylaminopyrimidine analogues(DAAPalogues)showing potent c-Met/ALK multikinase inhibitory activities[J].Med Chem Lett,2014,5(4):304-308.
    [51]
    Jason DK,James PJ,David JG,et al.Discovery of a 5H-benzo[4,5] cyclohepta[1,2-b] pyridin-5-one(MK-2461)inhibitor of c-Met kinase for the treatment of cancer[J].J Med Chem,2011,54(12):4092-4108.
    [52]
    Alan BN,Matthew HK,Michael DA,et al.Discovery of 1-[3-(1-methyl-1H-pyrazol -4-yl)-5-oxo-5H-benzo[4,5] cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide(MK-8033):a specific c-Met/RON dual kinase inhibitor with preferential affinity for the activated state of c-Met[J].J Med Chem,2013,56(6):2294-2310.
    • Related Articles

  • Related Articles

    [1]WANG Jing, LIU Hongxia, CAI Dongcheng, HE Chaoyong. Advances in pancreatic β-cell protective strategies[J]. Journal of China Pharmaceutical University, 2020, 51(5): 622-627. DOI: 10.11665/j.issn.1000-5048.20200515
    [2]ZHAO Mengqi, LIAO Hong. Researches progress of the relationship between neuro-inflammation and cognitive function[J]. Journal of China Pharmaceutical University, 2019, 50(4): 497-504. DOI: 10.11665/j.issn.1000-5048.20190416
    [3]YU Haiyang, CHEN Song, XU Zheng, GAO Xiangdong, YAO Wenbing. Protective effect of fibroin peptides on Aβ25-35-induced injury in SH-SY5Y cells and its mechanism[J]. Journal of China Pharmaceutical University, 2017, 48(5): 609-613. DOI: 10.11665/j.issn.1000-5048.20170517
    [4]LI Yuyao, SONG Heng, CHENG Jian, AO Guizhen. Synthesis and biological evaluation of H2S donor ADT-OH derivatives[J]. Journal of China Pharmaceutical University, 2017, 48(3): 276-281. DOI: 10.11665/j.issn.1000-5048.20170304
    [5]WANG Xiaoli, WANG Zhaoya, WANG Linna, JI Hui, ZHANG Yihua, YIN Jian. Design, synthesis and evaluation of hydrogen sulfide-releasing derivatives of ring opening 3-n-butylphthalide as novel platelet aggregation inhibitors[J]. Journal of China Pharmaceutical University, 2016, 47(2): 158-162. DOI: 10.11665/j.issn.1000-5048.20160205
    [6]ZHAO Meishun, CHEN Jingrong, ZHENG Yaojie, YANG Hong. Protective effect of genistein on Aβ25-35-induced PC12 cells injury[J]. Journal of China Pharmaceutical University, 2014, 45(2): 227-231. DOI: 10.11665/j.issn.1000-5048.20140217
    [7]WU Mingming, FANG Lei, GOU Shaohua, CHEN Li. 以2-甲基-2-取代苯氧基丙酸为离去基团的铂(Ⅱ)配合物的合成、表征及细胞毒活性[J]. Journal of China Pharmaceutical University, 2013, 44(4): 303-306. DOI: 10.11665/j.issn.1000-5048.20130403
    [8]SHEN Yu. Perspectives on current protection system of traditional Chinese medicine[J]. Journal of China Pharmaceutical University, 2011, 42(2): 189-192.
    [9]Experimental Research of YZH on the Hepatic Protection[J]. Journal of China Pharmaceutical University, 2001, (6): 40-43.
    [10]Synthesis and Nerve Cell Protection Activities of Tetrahydro-acridine Der Ivatives[J]. Journal of China Pharmaceutical University, 2000, (6): 3-7.

Catalog

    Get Citation
    PDF
    XML
    Article views (2067) PDF downloads (3346) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：290277

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return